



# Marksans Pharma Ltd.

Date: 10<sup>th</sup> June, 2022

**BSE Limited**  
Corporate Relation Department  
Phiroze Jeejeeboi Towers,  
Dalal Street,  
Mumbai – 400001.  
Scrip Code: 524404

**National Stock Exchange of India Limited**  
Listing Department  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400051.  
Symbol: MARKSANS

**Sub: Disclosure of Related Party Transactions under Regulation 23(9) of SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sirs,

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosure of related party transactions of the Company and its subsidiaries for the half year ended 31<sup>st</sup> March, 2022.

This is for your information and records.

Thanking you,

Yours faithfully  
**For Marksans Pharma Limited**

**Harshavardhan Panigrahi**  
Company Secretary

Encl: As above

**Marksans Pharma Ltd**

11th, Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara,  
Andheri (W), Mumbai - 400 053 • Tel. : +91 22 4001 2000 • Email : info@marksanspharma.com  
www.marksanspharma.com

## Disclosure of related party transactions for the half year ended 31<sup>st</sup> March 2022

|        |  |                    |  |                    |   |                                   |   |  |   | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. |   |      |        |   |                   |        |                    |   |
|--------|--|--------------------|--|--------------------|---|-----------------------------------|---|--|---|--|---|------|--------|---|-------------------|--------|--------------------|---|
| Sr. No | Details of the party (listed entity /subsidiary) entering into the transaction |                    | Details of the counterparty              |                    |   | Type of related party transaction | Value of the related party transaction as approved by the audit committee | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction |  | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments |      |        | Details of the loans, inter-corporate deposits, advances or investments |                   |        |                    |   |
|        | Name   | PAN (Refer Note 1) | Name                                     | PAN (Refer Note 1) | Relationship of the counterparty with the listed entity or its subsidiary |                                   |   |  | Opening balance   | Closing balance  | Nature of indebtedness (loan/ issuance of debt/ any other etc.)   | Cost | Tenure | Nature (loan/ advance/ inter-corporate deposit/ investment)             | Interest Rate (%) | Tenure | Secured/ unsecured | Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage) |
| 1.     | Marksans Pharma Limited  |                    | Nova Pharmaceuticals Australasia Pty Ltd |                    | Subsidiary  | Sale of goods                     | 30,19,01,122 (Refer Note 2)   | 30,19,01,122                                     | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |   |
| 2.     | Marksans Pharma Limited  |                    | Bell, Sons and Co. (Druggists) Limited   |                    | Wholly-owned Subsidiary   | Sale of goods                     | NA  | 35,12,55,607                                     | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |   |
| 3.     | Marksans Pharma Limited  |                    | Relonchem Limited                        |                    | Wholly-owned Subsidiary   | Sale of goods                     | NA  | 59,97,63,711                                     | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |   |
| 4.     | Marksans Pharma Limited  |                    | Time-Cap Laboratories Inc.               |                    | Wholly-owned Subsidiary   | Sale of goods                     | NA  | 170,71,75,084                                    | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |   |
| 5.     | Marksans Pharma Limited  |                    | Bell, Sons and Co. (Druggists) Limited   |                    | Wholly-owned Subsidiary   | Guarantee                         | NA  | 24   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |   |
| 6.     | Marksans Pharma Limited  |                    | Relonchem Limited                        |                    | Wholly-owned Subsidiary   | Guarantee                         | NA  | 24   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |   |
| 7.     | Marksans Pharma Limited  |                    | Time-Cap Laboratories Inc.               |                    | Wholly-owned Subsidiary   | Guarantee                         | NA  | 8,82,305   | -   | -  | -   | -    | -      | -   | -                 | -      | -                  |   |
| 8.     | Marksans Pharma Limited  |                    | Nova Pharmaceuticals Australasia Pty Ltd |                    | Subsidiary  | Trade Receivables                 | -   | -  | 29,44,42,598  | 29,54,35,603   | -   | -    | -      | -   | -                 | -      | -                  |   |
| 9.     | Marksans Pharma Limited  |                    | Bell, Sons and Co. (Druggists) Limited   |                    | Wholly-owned Subsidiary   | Trade Receivables                 | -   | -  | (20,71,83,904)  | (17,18,24,600)   | -   | -    | -      | -   | -                 | -      | -                  |   |
| 10.    | Marksans Pharma Limited  |                    | Relonchem Limited                        |                    | Wholly-owned Subsidiary   | Trade Receivables                 | -   | -  | (27,36,47,758)  | (36,55,14,126)   | -   | -    | -      | -   | -                 | -      | -                  |   |
| 11.    | Marksans Pharma Limited  |                    | Time-Cap Laboratories Inc.               |                    | Wholly-owned Subsidiary   | Trade Receivables                 | -   | -  | 152,75,47,095   | 191,94,11,058  | -   | -    | -      | -   | -                 | -      | -                  |   |

|     |                            |  |                                     |                   |           |              |             |        |   |   |   |   |   |   |   |   |   |
|-----|----------------------------|--|-------------------------------------|-------------------|-----------|--------------|-------------|--------|---|---|---|---|---|---|---|---|---|
| 12. | Marksans Pharma Limited    | Bell, Sons and Co. (Druggists) Limited | Wholly-owned Subsidiary             | Trade Payables    | -         | -            | 38,807      | -      | - | - | - | - | - | - | - | - | - |
| 13. | Marksans Pharma Limited    | Relonchem Limited                      | Wholly-owned Subsidiary             | Trade Payables    | -         | -            | 8,02,125    | -      | - | - | - | - | - | - | - | - | - |
| 14. | Marksans Pharma Limited    | Time-Cap Laboratories Inc.             | Wholly-owned Subsidiary             | Trade Payables    | -         | -            | 2,41,05,962 | 49,293 | - | - | - | - | - | - | - | - | - |
| 15. | Marksans Pharma Limited    | Mr. Mark Saldanha                      | Promoter & Key Managerial Personnel | Rent Paid         | 53,26,668 | 53,26,668    | -           | -      | - | - | - | - | - | - | - | - | - |
| 16. | Marksans Pharma Limited    | Mr. Mark Saldanha                      | Promoter & Key Managerial Personnel | Remuneration Paid | -         | 1,77,02,987. | -           | -      | - | - | - | - | - | - | - | - | - |
| 17. | Marksans Pharma Limited    | Mrs. Sandra Saldanha                   | Promoter & Key Managerial Personnel | Remuneration Paid | -         | 35,20,782    | -           | -      | - | - | - | - | - | - | - | - | - |
| 18. | Marksans Pharma Limited    | Mr. Varddhman Vikramaditya Jain        | Key Managerial Personnel            | Remuneration Paid | -         | 68,74,914    | -           | -      | - | - | - | - | - | - | - | - | - |
| 19. | Marksans Pharma Limited    | Mr. Jitendra Sharma                    | Key Managerial Personnel            | Remuneration Paid | -         | 62,88,690    | -           | -      | - | - | - | - | - | - | - | - | - |
| 20. | Marksans Pharma Limited    | Mr. Harshavardhan Panigrahi            | Key Managerial Personnel            | Remuneration Paid | -         | 12,70,206    | -           | -      | - | - | - | - | - | - | - | - | - |
| 21. | Marksans Pharma Limited    | Mr. Abhinna Sundar Mohanty             | Non-executive Director              | Sitting Fees      | -         | 15,000       | -           | -      | - | - | - | - | - | - | - | - | - |
| 22. | Marksans Pharma Limited    | Mr. Seetharama Raju Bhuddharaju        | Non-executive Director              | Sitting Fees      | -         | 20,000       | -           | -      | - | - | - | - | - | - | - | - | - |
| 23. | Marksans Pharma Limited    | Mr. Digant Mahesh Parikh               | Non-executive Director              | Sitting Fees      | -         | 1,50,000     | -           | -      | - | - | - | - | - | - | - | - | - |
| 24. | Marksans Pharma Limited    | Mrs. Meena Rani Surana                 | Non-executive Director              | Sitting Fees      | -         | 15,000       | -           | -      | - | - | - | - | - | - | - | - | - |
| 25. | Time-Cap Laboratories Inc. | Mr. Mark Saldanha                      | Director                            | Remuneration Paid | -         | 53,64,720    | -           | -      | - | - | - | - | - | - | - | - | - |

Notes:

1. As per the Guidance Note/FAQs for disclosure of related party transactions dated 25th April, 2022, issued by the Stock Exchanges, since the Company is filing the RPT disclosure in PDF format, the PAN details are not disclosed.
2. The transactions are within the limit of omnibus approval granted by the Audit Committee.